Roche Leads The Way In Global-Local Tie-ups That Fuel Commercial Health Insurance In China
This article was originally published in PharmAsia News
Roche leads the way in working with China’s commercial healthcare insurance companies to design expanded treatments for cancer and other serious illnesses that patients pay mostly out of pocket.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.